Sign in →

Order Code AN2TS Antineuronal Nuclear Antibody Type 2 (ANNA-2) Titer, Serum (Non-Orderable)


Specimen Required


Only orderable as a reflex. For more information see:

DMS2 / Dementia, Autoimmune/Paraneoplastic Evaluation, Serum

ENS2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum

EPS2 / Epilepsy, Autoimmune/Paraneoplastic Evaluation, Serum

MDS2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum

MAS1 / Myelopathy, Autoimmune/Paraneoplastic Evaluation, Serum


Useful For

Only orderable as a reflex. For more information see:

DMS2 / Dementia, Autoimmune/Paraneoplastic Evaluation, Serum

ENS2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum

EPS2 / Epilepsy, Autoimmune/Paraneoplastic Evaluation, Serum

MDS2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum

MAS1 / Myelopathy, Autoimmune/Paraneoplastic Evaluation, Serum

 

Serological evaluation of patients who present with a subacute neurological disorder and signs of midbrain/cerebellar/brain stem disorder and/or myelopathy, especially women with a previous history of breast cancer, and both sexes if there is a history of tobacco use or passive exposure

 

Directing a focused search for cancer

 

Investigating neurological symptoms that appear during, or after, cancer therapy, and are not explainable by metastasis

 

Reporting an end titer result from serum specimens

Testing Algorithm

If the indirect immunofluorescence (IFA) pattern suggests antineuronal nuclear antibody type 2 (ANNA-2), then this test will be performed at an additional charge.

Method Name

Only orderable as a reflex. For more information see:

DMS2 / Dementia, Autoimmune/Paraneoplastic Evaluation, Serum

ENS2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum

EPS2 / Epilepsy, Autoimmune/Paraneoplastic Evaluation, Serum

MDS2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum

MAS1 / Myelopathy, Autoimmune/Paraneoplastic Evaluation, Serum

 

Indirect Immunofluorescence Assay (IFA)

Reporting Name

ANNA-2 Titer, S

Specimen Type

Serum

Specimen Minimum Volume

Serum: 0.6 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Refrigerated (preferred) 28 days
  Frozen  28 days
  Ambient  72 hours

Reject Due To

Gross hemolysis Reject
Gross lipemia Reject
Gross icterus Reject

Reference Values

Only orderable as a reflex. For more information see:

DMS2 / Dementia, Autoimmune/Paraneoplastic Evaluation, Serum

ENS2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum

EPS2 / Epilepsy, Autoimmune/Paraneoplastic Evaluation, Serum

MDS2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum

MAS1 / Myelopathy, Autoimmune/Paraneoplastic Evaluation, Serum

 

<1:240

Method Description

The patient's specimen is tested by a standardized immunofluorescence assay that uses a composite frozen section of mouse cerebrum, cerebellum, kidney, and gut tissues. After incubation with the specimen and washing, fluorescein-conjugated goat-antihuman IgG is applied. Neuron-specific autoantibodies are identified by their characteristic fluorescence staining patterns. Specimens that are scored positive for any neuronal nuclear or cytoplasmic autoantibody are titrated. Interference by coexisting non-neuron-specific autoantibodies can usually be eliminated by serologic absorption.(Unpublished Mayo method)

 

If antineuronal nuclear autoantibody type 1 (ANNA-1), antinuclear antibody, or antimitochondrial antibody titers equal or exceed ANNA-2, Western blot analysis may be required to establish ANNA-2 specificity with certainty.

Day(s) Performed

Monday through Sunday

Performing Laboratory

Mayo Clinic Laboratories in Rochester

CPT Code Information

86256

LOINC Code Information

Test ID Test Order Name Order LOINC Value
AN2TS ANNA-2 Titer, S 94343-1

 

Result ID Test Result Name Result LOINC Value
43432 ANNA-2 Titer, S 94343-1